8-KLeadership ChangesExhibits & Filings

Elevance Health, Inc. 8-K Report, Executive Changes (May 10, 2018)

Filed May 10, 2018For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) announced a significant leadership change via an 8-K filing on May 10, 2018. Brian T. Griffin resigned from his positions as Executive Vice President of the Company and Chief Executive Officer of IngenioRx, a key subsidiary. This departure is effective May 10, 2018. The company has furnished a press release detailing this announcement as an exhibit to the filing. This executive transition, particularly concerning the CEO of IngenioRx, may raise questions for investors regarding the strategic direction and operational continuity of this important business segment. Investors should closely review the accompanying press release for further details on the reasons for the departure and any immediate plans for succession or interim leadership, as these factors could influence the company's future performance and stock valuation.

Key Highlights

  • 1Brian T. Griffin resigns as Executive Vice President of Elevance Health (then Anthem, Inc.).
  • 2Brian T. Griffin also resigns as Chief Executive Officer of IngenioRx, a subsidiary.
  • 3The effective date of Mr. Griffin's resignation is May 10, 2018.
  • 4The company has filed an 8-K to report this material event.
  • 5A press release announcing the resignation is furnished as an exhibit (Exhibit 99.1).

Frequently Asked Questions

Brian T. Griffin was the Executive Vice President of Elevance Health (then Anthem, Inc.) and the Chief Executive Officer of IngenioRx, a subsidiary of the company.

IngenioRx is a subsidiary of Elevance Health, and Mr. Griffin's role as its CEO suggests it is a significant operational unit for the company, likely related to pharmacy benefits or health solutions.

Mr. Griffin's departure, particularly from his role at IngenioRx, could signal changes in strategy, operations, or leadership within that key business segment. Investors will be looking for information on the reasons for the resignation and the plan for leadership succession to assess the impact on the company's future performance.

The company has furnished a press release dated May 10, 2018, as Exhibit 99.1 to this 8-K filing, which should contain further details regarding the resignation.